文献速递浆细胞疾病造血干细胞移植与细胞治疗

复发性难治性多发性骨髓瘤患者启动与维持艾基奥仑赛疗效相关的患者、肿瘤及嵌合抗原受体T细胞特征

Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma.
PubMed 文献 · Br J Haematol · 2025-07-15

基于KarMMa研究(NCT03361748)的转化分析,评估接受单次艾基奥仑赛(ide-cel)输注的复发性难治性多发性骨髓瘤患者中,与疗效启动及维持相关的患者基线、肿瘤及CAR T细胞特征。基线肿瘤负荷(可溶性BCMA)和淋巴耗竭化疗后释放的稳态细胞因子是药效学反应的主要相关因素;缓解持续时间与肿瘤基因组特征及更稳健的CD4+ CAR T细胞扩增、更高水平的持续ide-cel和BCMA表达细胞的持续抑制相关。

要点

  • 基线可溶性BCMA水平和淋巴耗竭化疗后稳态细胞因子是药效学反应的主要相关因素。
  • 缓解持续时间与肿瘤基因组特征及更稳健的CD4+ CAR T细胞扩增相关。
  • 更高水平的持续ide-cel和BCMA表达细胞的持续抑制与缓解持续时间相关。

核心结论

  • 患者和微环境特征可能调节ide-cel的激活和扩增,从而影响反应启动的概率;肿瘤内在耐药特征和ide-cel的持续植入影响反应的持久性。

研究设计与样本

  • 基于KarMMa研究(NCT03361748)的转化分析,研究对象为接受过>4线治疗的复发性难治性多发性骨髓瘤患者,接受单次ide-cel输注。

主要发现

  • 基线肿瘤负荷(以可溶性BCMA衡量)和淋巴耗竭化疗后释放的稳态细胞因子水平是药效学反应的主要相关因素。
  • 缓解持续时间与肿瘤基因组特征及更稳健的CD4+ CAR T细胞扩增相关。
  • 缓解持续时间与更高水平的持续ide-cel和BCMA表达细胞的持续抑制相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed autologous chimeric antigen receptor (CAR) T-cell therapy, was studied in relapsed and refractory multiple myeloma after >4 prior lines of therapy in KarMMa (NCT03361748). Translational analyses evaluated patient baseline, tumour and CAR T-cell features associated with initiating and sustaining response to a single ide-cel infusion. Baseline tumour burden, measured by soluble BCMA, and homeostatic cytokine levels released after lymphodepleting chemotherapy were among the top correlates for pharmacodynamic response. Duration of response was associated with tumour genomic features and quality of engraftment indicated by more robust CD4+ CAR T-cell expansion, higher levels of persistent ide-cel and sustained suppression of BCMA-expressing cells. A working model is proposed whereby patient and microenvironment features that may modulate ide-cel activation and expansion influence the probability of response initiation, and that tumour-intrinsic resistance features and sustained engraftment of ide-cel influence the durability of responses.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Martin N, Thompson E, Stong N, et al. Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma. Br J Haematol. 2025. PMID: 40665490. doi:10.1111/bjh.70012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。